文献速递造血干细胞移植与细胞治疗

奥法木单抗联合泼尼松初治慢性GVHD的2期多中心试验

A phase 2 multicenter trial of ofatumumab and prednisone as initial therapy for chronic graft-versus-host disease.
PubMed 文献 · Blood Adv · 2022-01-01

这项单臂2期多中心试验评估奥法木单抗(第0、14天1000 mg IV)联合泼尼松(1 mg/kg/天)初治慢性GVHD的疗效与安全性,共38例。6个月NIH总缓解率62.5%,未优于预设60%历史基准,但事后分析提示优于48.6%的同期基准;12个月无失败生存53.1%,安全性可接受。

要点

  • 6个月NIH总缓解率62.5%,未达预设60%历史基准的优效标准
  • 事后分析中12个月CR/PR的FFS为33.5%,超过15%基准
  • 12个月FFS伴CR/PR与24个月内更成功停用激素相关(OR 8)

核心结论

  • 奥法木单抗联合泼尼松初治cGVHD安全性可接受并显示潜在疗效。
  • 6个月NIH总缓解率未优于预设60%历史基准,但事后分析提示可能优于同期基准。

研究设计与样本

  • 单臂2期多中心试验,为1期试验(n=12)的2期扩展部分,共纳入38例。
  • 干预为奥法木单抗1000 mg IV第0、14天联合泼尼松1 mg/kg/天。
  • 试验注册号NCT01680965。

主要发现

  • cGVHD总体NIH严重度为中度63%、重度37%,重叠亚型占74%,既往急性GVHD占82%。
  • 6个月临床医生报告及2014 NIH定义的ORR均为62.5%(单侧90%CI下限51.5%)。
  • 至二线治疗启动的中位时间为5.4个月(范围0.9–15.1个月)。
  • FFS在6个月为64.2%(95%CI 46.5–77.4%),12个月为53.1%(95%CI 35.8–67.7%)。

关键数值与推荐

  • 6个月ORR为62.5%,未优于预设历史基准60%。
  • 事后分析中6个月NIH缓解提示优于同期基于NIH的基准48.6%(前线西罗莫司/泼尼松,CTN 0801试验)。
  • 12个月FFS伴CR/PR为33.5%,超过事后分析基准15%。
  • 12个月FFS伴CR/PR与24个月内更成功停用激素相关(OR 8,95%CI 1.21–52.7)。

临床怎么用

  • 奥法木单抗联合泼尼松可作为cGVHD初治的潜在选择,但需注意其6个月缓解率未达预设优效基准。
  • 治疗决策时可参考12个月FFS伴CR/PR与后期激素停用的关联。

局限性

  • 单臂设计,无随机对照,结论受历史基准及事后分析限制。
  • 基线cGVHD特征(器官受累、严重度、初始免疫抑制药物)与6个月ORR无显著关联。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Standard initial therapy of chronic graft vs. host disease (cGVHD) with glucocorticoids results in suboptimal response. Safety and feasibility of therapy with ofatumumab (1000 mg IV on days 0 and 14) and prednisone (1 mg/kg/day) was previously established in our phase I trial (n = 12). We now report the mature results of the phase II expansion of the trial (n = 38). The overall NIH severity of cGVHD was moderate (63%) or severe (37%) with 74% of all patients affected by the overlap subtype of cGVHD and 82% by prior acute cGVHD. The observed 6 month clinician-reported and 2014 NIH-defined overall response rates (ORR = complete + partial response [CR/PR]) of 62.5% (1-sided lower 90% confidence interval=51.5%) were not superior to pre-specified historic benchmark of 60%. Post-hoc comparison of 6 month NIH response suggested benefit compared to more contemporaneous NIH-based benchmark of 48.6% with frontline sirolimus/prednisone (CTN 0801 trial). Baseline cGVHD features (organ involvement, severity, initial immune suppression agents) were not significantly associated with 6-month ORR. The median time to initiation of second-line therapy was 5.4 months (range 0.9-15.1 months). Failure-free survival (FFS) was 64.2% (95% CI 46.5-77.4%) at 6 months and 53.1% (95% CI 35.8-67.7%) at 12 months, whereas FFS with CR/PR at 12 months of 33.5% exceeded a benchmark of 15% in post-hoc analysis, and was associated with greater success in steroid discontinuation by 24 months (odds ratio 8 (95% CI 1.21-52.7). This single-arm phase II trial demonstrated acceptable safety and potential efficacy of the upfront use of ofatumumab in combination with prednisone in cGVHD. This trial was registered at www.clinicaltrials.gov as #NCT01680965.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Lazaryan A, Lee S, Arora M, et al. A phase 2 multicenter trial of ofatumumab and prednisone as initial therapy for chronic graft-versus-host disease. Blood Adv. 2022. PMID: 34649279. doi:10.1182/bloodadvances.2021005552

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。